I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products
Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.
The PCN agreed the attached Spondyloarthritis biologic treatment pathway in line with TA383 which was published by NICE in February 2016. The PCN previously (March 2016) supported the branded prescribing of biosimilar etanercept (Benepali) to be used in all new patients for all indications where they have licensing authorisation in the UK. Switching to Benepali has been discussed locally with acute trusts and specialists.
